Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Relay TherapeuticsRLAY +0.40%46 Market Cap is $4,400.36 Mil as of Aug. 13, 2026. GuruFocus rates RLAY with a GF Score™ of 46/100 and a GF Value™ of $3.80 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,421 Biotechnology companies, Relay Therapeutics ranks better than 93.38% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Relay Therapeutics's share price for the quarter that ended in Jun. 2026 was $18.71. Relay Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 218.53 Mil. Therefore, Relay Therapeutics's market cap for the quarter that ended in Jun. 2026 was $4,088.72 Mil.
Relay Therapeutics's quarterly market cap
increased
from Dec. 2025 ($1,470.93 Mil) to Mar. 2026 ($1,882.63 Mil) and
increased
from Mar. 2026 ($1,882.63 Mil) to Jun. 2026 ($4,088.72 Mil).
Relay Therapeutics's annual market cap
declined
from Dec. 2023 ($1,403.36 Mil) to Dec. 2024 ($691.15 Mil) but then
increased
from Dec. 2024 ($691.15 Mil) to Dec. 2025 ($1,470.93 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Relay Therapeutics's Enterprise Value for Today is $3,517.90 Mil.
Relay Therapeutics (NAS:RLAY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Relay Therapeutics Market Cap Related Terms
Relay Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Relay Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Relay Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relay Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relay Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Relay Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Relay Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relay Therapeutics (RLAY) has a Market Cap of $4,400.36 Mil as of Aug. 13, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Relay Therapeutics and its competitors. According to the industry distribution chart, Relay Therapeutics ranks #94 out of 1421 companies in the Biotechnology industry, placing it in the top 6.6%.
Is Relay Therapeutics' Market Cap too high?
Relay Therapeutics' current Market Cap is $4,400.36 Mil. The Biotechnology industry median Market Cap is 118.28. Relay Therapeutics' value of $4,400.36 Mil is 3620.3% above this industry median. Based on the distribution chart, Relay Therapeutics ranks #94 out of 1421 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Relay Therapeutics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Relay Therapeutics' Market Cap compare to CELC and VKTX?
According to the Biotechnology industry distribution chart, Relay Therapeutics ranks #94 out of 1421 companies for Market Cap. This places Relay Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median Market Cap is 118.28. Relay Therapeutics' value of $4,400.36 Mil is 3620.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 118.28, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relay Therapeutics's current Market Cap of $4,400.36 Mil is 3620.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Relay Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 118.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relay Therapeutics's current Market Cap is $4,400.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relay Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Relay Therapeutics (RLAY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.80, compared to a current price of $20.08 — trading 428.4% above its estimated fair value. The current Market Cap is $4,400.36 Mil and 3620.3% above the Biotechnology industry median of 118.28. Relay Therapeutics' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Relay Therapeutics (RLAY), the current Market Cap is $4,400.36 Mil as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relay Therapeutics (RLAY) Overvalued in 2026?
Based on GuruFocus' analysis, Relay Therapeutics stock appears to be overvalued.
The current stock price of $20.08 is trading 428.4% above its estimated GF Value™ of $3.80.
GuruFocus considers Relay Therapeutics to be Significantly Overvalued.
Key valuation signals for RLAY:
Market Cap: $4,400.36 Mil
GF Value™: $3.80 vs. price of $20.08 (428.4% above fair value)
Industry Position: 3620.3% above the Biotechnology median (#94 of 1421)
No single metric tells the full story. See the RLAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
46GF Score
Get the complete analysis for RLAY
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLAY has been successfully added to your 
